Advanced search
Publication Cover
Leukemia & Lymphoma Volume 56, 2015 - Issue 3
Submit an article Journal homepage
957
Views
13
CrossRef citations to date
0
Altmetric
Clinical Dilemma

How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?

Constantine S. TamHaematology Department, Peter MacCallum Cancer Center, East Melbourne, Victoria, AustraliaCorrespondence[email protected]
&
Stephan StilgenbauerDepartment of Internal Medicine III, Ulm University, Ulm, Germany
Pages 587-593 | Received 15 Jan 2015, Accepted 17 Jan 2015, Published online: 17 Feb 2015

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Stefano Molica. (2015) Highlights in the treatment of chronic lymphocytic leukemia from the 2014 meeting of the American Society of Hematology. Expert Review of Hematology 8:3, pages 277-281.
Read now

Articles from other publishers (12)

Xinyue Wang, Xiao Tan, Jinping Zhang, Jiaping Wu & Hongjuan Shi. (2023) The emerging roles of MAPK-AMPK in ferroptosis regulatory network. Cell Communication and Signaling 21:1.
Crossref
Andrew Davies, Arnon P Kater, Jeff P Sharman, Stephan Stilgenbauer, Umberto Vitolo, Christian Klein, Joana Parreira & Gilles Salles. (2022) Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review. Future Oncology 18:26, pages 2943-2966.
Crossref
Shaun Egolf, Jonathan Zou, Amy Anderson, Cory L. Simpson, Yann Aubert, Stephen Prouty, Kai Ge, John T. Seykora & Brian C. Capell. (2021) MLL4 mediates differentiation and tumor suppression through ferroptosis. Science Advances 7:50.
Crossref
Sanem Gökçen, E.Ümit Bağrıaçık, Handan Kayhan & Münci Yağcı. (2021) Immunomolecular evaluation of dihydroartemisinin effects on apoptosis in chronic lymphocytic leukemia cell lines. Leukemia Research 110, pages 106702.
Crossref
Daiki Makieda, Satoru Esumi & Kiminaka Murakawa. (2021) Drug interaction (51. New oral anticancer drugs in hematological malignancies and drug interactions)薬物相互作用（51―造血器腫瘍領域の新規経口抗がん剤と薬物相互作用）. Okayama Igakkai Zasshi (Journal of Okayama Medical Association) 133:2, pages 120-126.
Crossref
Yunpeng Wei, Huanhuan Lv, Atik Badshah Shaikh, Wei Han, Hongjie Hou, Zhihao Zhang, Shenghang Wang & Peng Shang. (2020) Directly targeting glutathione peroxidase 4 may be more effective than disrupting glutathione on ferroptosis-based cancer therapy. Biochimica et Biophysica Acta (BBA) - General Subjects 1864:4, pages 129539.
Crossref
Bo Chu, Ning Kon, Delin Chen, Tongyuan Li, Tong Liu, Le Jiang, Shujuan Song, Omid Tavana & Wei Gu. (2019) ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway. Nature Cell Biology 21:5, pages 579-591.
Crossref
Jeffrey Jones, Anthony Mato, Steven Coutre, John C. Byrd, Richard R. Furman, Peter Hillmen, Anders Osterborg, Constantine Tam, Stephan Stilgenbauer, William G. Wierda, Nyla A. Heerema, Karl Eckert, Fong Clow, Cathy Zhou, Alvina D. Chu, Danelle F. James & Susan M. O'Brien. (2018) Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. British Journal of Haematology 182:4, pages 504-512.
Crossref
John F. SeymourThomas J. KippsBarbara EichhorstPeter HillmenJames D’RozarioSarit AssoulineCarolyn OwenJohn GerecitanoTadeusz RobakJavier De la SernaUlrich JaegerGuillaume CartronMarco MontilloRod HumerickhouseElizabeth A. PunnooseYan LiMichelle BoyerKathryn HumphreyMehrdad MobasherArnon P. Kater. (2018) Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. New England Journal of Medicine 378:12, pages 1107-1120.
Crossref
A Stengel, W Kern, T Haferlach, M Meggendorfer, A Fasan & C Haferlach. (2016) The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases. Leukemia 31:3, pages 705-711.
Crossref
Caleb Ho & Michael J. Kluk. (2016) Molecular Pathology. Surgical Pathology Clinics 9:3, pages 489-521.
Crossref
E Montserrat & J Delgado. (2016) CLL: ibrutinib and transplantation ride together. Bone Marrow Transplantation 51:6, pages 769-770.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.